Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT Trial
Adnan Nagrial(Westmead Hospital), Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre), Wei‐Sen Lam(Fiona Stanley Hospital), Craig Underhill(AstraZeneca (United Kingdom)), Rosemary Harrup(University of Tasmania), Robert Zielinski, Michael P. Brown(South Australia Pathology), Ashray Gunjur(Wellcome Sanger Institute), Damien Kee(Peter MacCallum Cancer Centre), Jonathan Cebon(La Trobe University), Ian Collins(St. James's Hospital), Sam Harris, John M. Mariadason(Olivia Newton-John Cancer Wellness & Research Centre), John P. Grady(Garvan Institute of Medical Research), David M. Thomas(New South Wales Department of Health), Fiona Chionh, Mandy L. Ballinger(Garvan Institute of Medical Research), Matteo S. Carlino(The University of Sydney), Elnaz Tavancheh(Olivia Newton-John Cancer Wellness & Research Centre), Michael Michael(Ospedale San Donato), Charles John T. Uy, Kylie Wilkie, Javier Torres, Jane Y. So, Howard Chan, Jodie Palmer(Olivia Newton-John Cancer Wellness & Research Centre)
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k